Below is a list of Moderna’s board members. Details on our board committees and committee composition can be found here.
- Noubar Afeyan, Ph.D., Co-founder and Chairman, Moderna; CEO, Flagship Pioneering
- Stéphane Bancel, Chief Executive Officer, Moderna
- Stephen Berenson, Managing Partner, Flagship Pioneering
- Sandra Horning, M.D., Co-founder and Advisor, EQRx
- Robert Langer, Sc.D., Academic Co-Founder, Moderna; David H. Koch Institute Professor, MIT
- Elizabeth Nabel, M.D., President, Brigham Health
- François Nader, M.D., Former President, CEO and Executive Director, NPS Pharmaceuticals
- Paul Sagan, Managing Director, General Catalyst
- Henri A. Termeer, Retired Chairman, President, and CEO of Genzyme - In Memoriam
Noubar Afeyan, Ph.D.
Co-founder and Chairman, Moderna; CEO, Flagship Pioneering
Noubar Afeyan, Ph.D., is co-founder and chairman of Moderna, and CEO of Flagship Pioneering, a leading early stage venture capital firm. He also leads the firm’s VentureLabs unit that invents and launches transformative startups. He is a senior lecturer at MIT’s Sloan School of Management where he has taught courses on technology entrepreneurship, innovation, and leadership since 2000. Dr. Afeyan has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. He lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation, and venture capital to biological engineering, drug discovery, medical technologies, and renewable energy. During his 24-year career as inventor, entrepreneur, CEO and venture capitalist, Dr. Afeyan has co-founded and helped build 24 successful life science and technology startups.
Currently Dr. Afeyan serves on a number of public and private company boards in addition to Moderna, and he is a member of several advisory boards including the Yale Climate & Energy Initiative and the SKOLKOVO School of Management in Moscow. He is also a member of the board of overseers of the Boston Symphony Orchestra. Previously, he was founder and CEO of PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100 million in annual sales within six years from its first sales, and he was a member of the founding team, director, and investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), and Adnexus Therapeutics (acquired by Bristol-Myers Squibb).
Chief Executive Officer, Moderna
Stéphane Bancel joined Moderna joined Moderna in the summer of 2011 when it was a one employee company. He has assembled a world-class team and raised nearly $2 billion between equity financing and upfront from licensing collaborations.
He was previously CEO of bioMérieux, a world leader in the diagnostics industry. bioMérieux had more than 6,000 employees, a market capitalization of €2.5 billion, and sales of more than €1.3 billion.
Prior to his time at bioMérieux, Mr. Bancel was the managing director of Eli Lilly Belgium and executive director of global manufacturing strategy and supply chain at Eli Lilly in Indianapolis, Indiana. He started at Lilly in their UK manufacturing plant outside London.
He holds a Master of Engineering from École Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School.
Mr. Bancel was named Ernst & Young 2017 New England Entrepreneur of the Year. He was ranked the number one CEO in the biotech sector according to the 2011 Thomson Reuters EXTEL Study. In 2009, he was elected a Young Global Leader by the World Economic Forum, and elected best CEO for investor relations in France.
Mr. Bancel serves as a supervisory director of Qiagen N.V. He also serves on the Board of Trustees for the Museum of Science, Boston.
Managing Partner, Flagship Pioneering
Stephen Berenson is managing partner at Flagship Pioneering and is a member of the firm’s Investment and Management Committees. He focuses on capital formation at the fund and portfolio company levels and helps the firm’s management teams grow and realize value. Mr. Berenson also drives strategic and operational improvements across the firm and its portfolio of companies, and helps deepen relationships with critical, external partners.
Mr. Berenson joined Flagship after a 33-year career as an investment banker at J.P. Morgan. During that time, he worked across all major geographies, product areas and industry groups, and he was a key player in building the bank’s M&A, equities and technology investment banking businesses. During his last twelve years at J.P. Morgan, Mr. Berenson was vice chairman of investment banking and focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was co-founder of J.P Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. During Mr. Berenson's leadership of the Board Initiative, more than 1,000 independent directors of public companies attended at least one of J.P. Morgan’s board events to discuss, debate and share best practices on the key issues they faced in the fulfillment of their duties.
Mr. Berenson also made important contributions to J.P. Morgan’s culture through his deep support of recruiting, training and development, and mentoring, and he helped to build and maintain a robust control environment through his participation on the firm’s Equity Underwriting and Reputational Risk Committees.
Mr. Berenson graduated from MIT in 1982 with an S.B. in mathematics. He is a member of the board of trustees of the Mahaiwe Performing Arts Center in Great Barrington, Massachusetts.
Sandra Horning, M.D.
Co-founder and Advisor, EQRx
Sandra Horning, M.D., FACP, FASCO, is an academic and industry veteran, currently a co-founder and advisor for EQRx, a biotechnology company focused on creating innovative medicines at lower prices. Dr. Horning previously served as Chief Medical Officer and Head of Global Product Development at Genentech/Roche (SIX: RO, ROG; OTCQX: RHHBY) from 2014 to 2019. Over the course of a decade in industry, she oversaw the approval of 15 new medicines across a variety of diseases, including cancer, multiple sclerosis, influenza and blindness. Prior to joining Genentech, Dr. Horning was a Professor of Medicine, Oncology and Blood and Bone Marrow Transplantation at Stanford University for more than 20 years, where she remains an Emerita Professor.
Dr. Horning currently serves on the Board of Directors of Gilead Sciences, Inc. (Nasdaq: GILD). She has received numerous awards and recognitions throughout her career – she is the recipient of the Healthcare Businesswomen’s Association 2020 Woman of the Year, 2017 Duane Roth Memorial Award, 2014 Fierce Biotech Top Women in Biotech Award and 2010 Top Women in Bay Area Business Award. She was President of the American Society of Clinical Oncology from 2005-2006, has served on the editorial boards of multiple peer-reviewed medical journals, including Journal of Clinical Oncology, Clinical Cancer Research, Clinical Lymphoma, Leukemia & Lymphoma, the Annals of Internal Medicine and the American Journal of Medicine, and has authored more than 300 publications.
Dr. Horning received her M.D. from University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University.
Robert Langer, Sc.D.
Academic Co-Founder, Moderna; David H. Koch Institute Professor, MIT
Robert S. Langer, Sc.D., is the David H. Koch Institute Professor at MIT (there are 14 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). Dr. Langer has written more than 1,180 articles. He also has approximately 800 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to more than 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history.
He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 to 2002, and as its Chairman from 1999 to 2002.
Dr. Langer has received over 250 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineer; the 2008 Millennium Prize, the world’s largest technology prize; and the 2012 Priestley Medal, the highest award of the American Chemical Society. He is the also the only engineer to receive the Gairdner Foundation International Award; 72 recipients of this award have subsequently received a Nobel Prize. Among numerous other awards Langer has received are the Dickson Prize for Science (2002), Heinz Award for Technology, Economy and Employment (2003), the Harvey Prize (2003), the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright), the General Motors Kettering Prize for Cancer Research (2004), the Dan David Prize in Materials Science (2005), the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research, induction into the National Inventors Hall of Fame (2006), the Max Planck Research Award (2008), and the Prince of Asturias Award for Technical and Scientific Research (2008). In 1998, he received the Lemelson-MIT prize, the world’s largest prize for invention, for being “one of history’s most prolific inventors in medicine.” In 1989 Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. He is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction.
Elizabeth Nabel, M.D.
President, Brigham Health
Elizabeth (Betsy) Nabel, M.D., has served as president of Harvard-affiliated Brigham Health--an academic health care system which includes Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, and the Brigham and Women’s Physician Organization--since 2010. A cardiologist and distinguished biomedical researcher, Dr. Nabel is Professor of Medicine at Harvard Medical School.
Dr. Nabel brings a unique perspective to health care based on her experience as a physician, research scientist, academic medicine leader, and wellness advocate. At Brigham Health, Dr. Nabel is leading development of a new model of academic medicine devoted to maintaining and restoring health through leadership in scientific discovery, education, and compassionate care. Initiatives include a new translational research and clinical facility, leading-edge care redesign, and a $1.5 billion campaign to advance life-giving breakthroughs.
Building on her lifelong commitment to improving health through science, in 2015 Dr. Nabel was appointed chief health and medical advisor to the National Football League. In this newly created advisory role, Dr. Nabel provides strategic input to the NFL’s medical, health and scientific efforts; participates as an ex-officio member on each of the NFL’s medical advisory committees; and identifies areas for the NFL to enhance player safety, care and treatment.
Dr. Nabel has a long record of advocacy for health and broadening access to care. As director of the National Heart, Lung, and Blood Institute from 2005-2009, Dr. Nabel leveraged the $3 billion research portfolio to establish pioneering scientific programs in genomics, stem cells, and translational research. One of her signature advocacy efforts was the Red Dress Heart Truth campaign, which raises heart awareness in women through unprecedented industry partnerships.
An accomplished physician-scientist, Dr. Nabel’s work on the molecular genetics of cardiovascular diseases has produced17 patents and more than 250 scientific publications. Dr. Nabel’s scientific contributions in cardiovascular gene transfer have developed molecular and cellular techniques, delineated that the pathophysiology of atherosclerosis and clarified the processes of cell division and growth of vascular smooth muscle cells in blood vessels. Her studies on Hutchinson-Gilford Progeria Syndrome have characterized the vascular smooth muscle cell defect leading to premature heart attack and stroke.
Dr. Nabel has been named one of the nation’s top leaders in medicine by Modern Healthcare and Becker’s Hospital Review, and one of Boston’s 50 most powerful people by Boston Magazine. Her honors include the Distinguished Bostonian Award from the Greater Boston Chamber of Commerce, the Kober Medal from the Association of American Physicians, the Champion in Health Care award from the Boston Business Journal, the Willem Einthoven Award from Leiden University in the Netherlands, the Amgen-Scientific Achievement Award, two Distinguished Achievement Awards and the Eugene Braunwald Academic Mentorship Award from the American Heart Association, and six honorary doctorates.
Her colleagues have elected her to the American Academy of the Arts and Sciences, the National Academy of Medicine, the Association of American Physicians, the American Society of Clinical Investigation, and she is a Fellow of the American Association for the Advancement of Science. Dr. Nabel also serves on the boards of Medtronic, the Broad Institute, Ariadne Labs, the Boys & Girls Club of Boston, and the Medical Advisory Board of the Howard Hughes Medical Institute, and previously served on the editorial boards for the New England Journal of Medicine, Science, and Science Translational Medicine as well as editor-in-chief of Scientific American Medicine.
A native of St. Paul, Minnesota, Dr. Nabel attended Weill Cornell Medical College and completed her internal medicine and cardiology training at Brigham and Women’s Hospital. She and her husband Gary, who is the chief scientific officer for Sanofi, have three children, all of whom are pursuing careers in medicine.
François Nader, M.D.
Former President, CEO and Executive Director, NPS Pharmaceuticals
François Nader, M.D. is an experienced biopharmaceutical executive and director with broad expertise across development, regulatory affairs and commercial. Dr. Nader served as President, Chief Executive Officer and Executive Director of NPS Pharmaceuticals from 2008 until 2015, when the company was acquired by Shire (now part of Takeda (NYSE: TAK)). During his tenure as CEO, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. Prior to NPS, Dr. Nader was a venture partner at Care Capital, a venture capital firm. He previously served on Aventis Pharma’s North America Leadership Team, holding a number of executive positions in integrated healthcare markets and medical and regulatory affairs. Dr. Nader previously led global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc (now part of Sanofi (NASDAQ: SNY)).
In addition to serving on the Moderna board of directors, Dr. Nader currently serves as Chairman of the board of directors of Acceleron Pharma (NASDAQ: XLRN), Prevail Therapeutics (NASDAQ: PRVL) and Talaris Therapeutics. He also serves on the Board of Directors of Alexion Pharmaceuticals (NASDAQ: ALXN) and advisor for SVB-Leerink. Dr. Nader is the past Chairman of BioNJ, New Jersey’s biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization (BIO), NPS Pharma (NASDAQ: NPSP), Advanced Accelerator Applications (NASDAQ: AAAP), Baxalta (NYSE: BXLT), Clementia Pharmaceuticals (NASDAQ: CMTA), Trevena (NASDAQ: TRVN) and Noven (NASDAQ: NOVN). In 2013, he was recognized as the Ernst and Young National Life Science Entrepreneur of the Year.
Dr. Nader earned his French doctorate in medicine from St. Joseph University in Lebanon and a physician executive MBA from the University of Tennessee.
Managing Director, General Catalyst
Paul Sagan is a Managing Director at the venture capital firm General Catalyst, where he focuses on investments in internet software, services, and infrastructure companies. He was previously an executive in residence (XIR) at the firm.
Prior to joining General Catalyst, Mr. Sagan was CEO of Akamai Technologies, a pioneer in internet content delivery, application performance and cloud security, and now one of the largest cloud services providers. He joined Akamai in October 1998 as chief operating officer, became president the following year, and was CEO from April 2005 until 2013. Mr. Sagan was elected to the Akamai Board of Directors in January 2005 and served until 2019.
Mr. Sagan is also a director of VMware, Inc. Previously, he served as a director of iRobot Corp, as well as Catalina Labs (acquired by Asurion), Dow Jones & Company (acquired by News Corp.), Digitas, Inc. (acquired by Publicis Group), EMC Corp. (acquired by Dell Technologies), and Maven Networks (acquired by Yahoo!).
Mr. Sagan began his career as a television journalist and his work was recognized with three Emmy Awards for broadcast news in New York City. Later he joined Time Warner to co-found three businesses: NY1, the 24-hour cable news network; Roadrunner, the world’s first consumer broadband service; and Pathfinder, one of the first internet advertising platforms.
President Obama appointed Mr. Sagan to the President's National Security Telecommunications Advisory Committee in 2010 and he served until 2017.
He has been a fellow of the American Academy of Arts and Sciences since 2008, and in 2009 was named Ernst & Young’s Entrepreneur of the Year in the technology category. In 1996 the World Economic Forum named Mr. Sagan a Global Leader for Tomorrow.
Mr. Sagan is a graduate of the Medill School of Journalism at Northwestern University, where he is a life trustee. He also serves as Chairman of the Board of Directors of ProPublica, and was appointed by Governor Charlie Baker to be Chairman of the Massachusetts Board of Elementary and Secondary Education from 2015 to 2019.
Henri A. Termeer - In Memoriam
Retired Chairman, President, and CEO of Genzyme
Henri A. Termeer served as chairman, president, and chief executive officer of Genzyme Corporation for nearly three decades. Mr. Termeer was appointed president of Genzyme in 1983, two years after the company’s founding. He became its chief executive officer in 1985 and chairman in 1988. He retired from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion.
Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer was active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care.
Mr. Termeer was a board member of Massachusetts Institute of Technology Corporation and served on its executive committee, a director of Massachusetts General Hospital, board member of Partners HealthCare, a member of the Board of Fellows of Harvard Medical School, and on the board of the Biotechnology Industry Organization (BIO). He also served on the boards of Abiomed, Inc., AVEO Pharmaceuticals, Verastem, Inc., and Medical Simulation Corporation. In 2008, he was appointed to Massachusetts Governor Deval Patrick’s Council of Economic Advisors and was a co-chair of the Leadership Council of the Massachusetts Life Sciences Collaborative. Mr. Termeer was also chairman emeritus of the New England Healthcare Institute, a nonprofit, applied research health policy organization he was instrumental in founding. He was elected a fellow of the American Academy of Arts and Sciences in 1999.
Mr. Termeer was chairman of the Federal Reserve Bank of Boston’s board of directors from 2010-2011 and served on the board of directors of the Pharmaceutical Research and Manufacturers of America. Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an MBA from the Darden School at the University of Virginia. Mr. Termeer has been recognized by several highly regarded organizations for his contributions to the health care and entrepreneurial fields.